Neurocarrus
Neurocarrus, with a valuation of $11.25 million, is raising funds on Wefunder. The company has developed the drug candidate N-001 to provide neuron-specific pain relief without risk of addiction. Neurocarrus’ N-001 is a first-in-class, long-acting aesthetic-like drug that could reduce or avoid opioid use and targets neurons to calm their excessive activity that causes pain. The company is led by an experienced team and has patents issued on exclusively licensed technology in the US and other countries. Paul Blum founded Neurocarrus in October 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $124,000. The campaign proceeds will be used for salaries, contract research organisation services for pre-clinical development, consultants for FDA review, manufacturing, and operations.
Neurocarrus, with a valuation of $11.25 million, is raising funds on Wefunder. The company has developed the drug candidate N-001 to provide neuron-specific pain relief without risk of addiction. Neurocarrus’ N-001 is a first-in-class, long-acting aesthetic-like drug that could reduce or avoid opioid use and targets neurons to calm their excessive activity that causes pain. The company is led by an experienced team and has patents issued on exclusively licensed technology in the US and other countries. Paul Blum founded Neurocarrus in October 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $124,000. The campaign proceeds will be used for salaries, contract research organisation services for pre-clinical development, consultants for FDA review, manufacturing, and operations.
Stay in the Loop
Get updates from Neurocarrus
Get exclusive updates from Neurocarrus
Be the first to know about company milestones, news, and opportunities.
đź”’ No spam. Just real progress.
Company Stats
Key metrics about Neurocarrus
Are you the owner of Neurocarrus?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company